CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum.

Peter C. Gerszten, Cihat Ozhasoglu, Steven A. Burton, William C. Welch, William J. Vogel, Barbara A. Atkins, Shalom Kalnicki

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

OBJECT: The role of stereotactic radiosurgery for the treatment of intracranial lesions is well established. The experience with radiosurgery for the treatment of spinal and sacral lesions is more limited. Sacral lesions should be amenable to radiosurgical treatment similar to that used for their intracranial counterparts. The authors evaluated a single- fraction radiosurgical technique performed using the CyberKnife Real-Time Image-Guided Radiosurgery System for the treatment of the sacral lesion. METHODS: The CyberKnife is a frameless radiosurgery system based on the coupling of an orthogonal pair of x-ray cameras to a dynamically manipulated robot-mounted linear accelerator possessing six degrees of freedom, which guides the therapy beam to the intended target without the need for frame-based fixation. All sacral lesions were located and tracked for radiation delivery relative to fiducial bone markers placed percutaneously. Eighteen patients were treated with single-fraction radiosurgery. Tumor histology included one benign and 17 malignant tumors. Dose plans were calculated based on computerized tomography scans acquired using 1.25-mm slices. Planning treatment volume was defined as the radiographically documented tumor volume with no margin. Tumor dose was maintained at 12 to 20 Gy to the 80% isodose line (mean 15 Gy). Tumor volume ranged from 23.6 to 187.4 ml (mean 90 ml). The volume of the cauda equina receiving greater than 8 Gy ranged from 0 to 1 ml (mean 0.1 ml). All patients underwent the procedure in an outpatient setting. No acute radiation toxicity or new neurological deficits occurred during the mean follow-up period of 6 months. Pain improved in all 13 patients who were symptomatic prior to treatment. No tumor progression has been documented on follow-up imaging. CONCLUSIONS: Stereotactic radiosurgery was found to be feasible, safe, and effective for the treatment of both benign and malignant sacral lesions. The major potential benefits of radiosurgical ablation of sacral lesions are relatively short treatment time in an outpatient setting and minimal or no side effects. This new technique offers a new and important therapeutic modality for the primary treatment of a variety of sacral tumors or for lesions not amenable to open surgical techniques.

Original languageEnglish (US)
JournalNeurosurgical Focus
Volume15
Issue number2
StatePublished - 2003
Externally publishedYes

Fingerprint

Sacrum
Radiosurgery
Neoplasms
Therapeutics
Tumor Burden
Outpatients
Fiducial Markers
Radiation
Cauda Equina
Particle Accelerators
Histology
Tomography
X-Rays

Cite this

Gerszten, P. C., Ozhasoglu, C., Burton, S. A., Welch, W. C., Vogel, W. J., Atkins, B. A., & Kalnicki, S. (2003). CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. Neurosurgical Focus, 15(2).

CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. / Gerszten, Peter C.; Ozhasoglu, Cihat; Burton, Steven A.; Welch, William C.; Vogel, William J.; Atkins, Barbara A.; Kalnicki, Shalom.

In: Neurosurgical Focus, Vol. 15, No. 2, 2003.

Research output: Contribution to journalArticle

Gerszten, PC, Ozhasoglu, C, Burton, SA, Welch, WC, Vogel, WJ, Atkins, BA & Kalnicki, S 2003, 'CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum.', Neurosurgical Focus, vol. 15, no. 2.
Gerszten PC, Ozhasoglu C, Burton SA, Welch WC, Vogel WJ, Atkins BA et al. CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. Neurosurgical Focus. 2003;15(2).
Gerszten, Peter C. ; Ozhasoglu, Cihat ; Burton, Steven A. ; Welch, William C. ; Vogel, William J. ; Atkins, Barbara A. ; Kalnicki, Shalom. / CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum. In: Neurosurgical Focus. 2003 ; Vol. 15, No. 2.
@article{730e54310c5d4ae5bdc37b2f0cda6e3b,
title = "CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum.",
abstract = "OBJECT: The role of stereotactic radiosurgery for the treatment of intracranial lesions is well established. The experience with radiosurgery for the treatment of spinal and sacral lesions is more limited. Sacral lesions should be amenable to radiosurgical treatment similar to that used for their intracranial counterparts. The authors evaluated a single- fraction radiosurgical technique performed using the CyberKnife Real-Time Image-Guided Radiosurgery System for the treatment of the sacral lesion. METHODS: The CyberKnife is a frameless radiosurgery system based on the coupling of an orthogonal pair of x-ray cameras to a dynamically manipulated robot-mounted linear accelerator possessing six degrees of freedom, which guides the therapy beam to the intended target without the need for frame-based fixation. All sacral lesions were located and tracked for radiation delivery relative to fiducial bone markers placed percutaneously. Eighteen patients were treated with single-fraction radiosurgery. Tumor histology included one benign and 17 malignant tumors. Dose plans were calculated based on computerized tomography scans acquired using 1.25-mm slices. Planning treatment volume was defined as the radiographically documented tumor volume with no margin. Tumor dose was maintained at 12 to 20 Gy to the 80{\%} isodose line (mean 15 Gy). Tumor volume ranged from 23.6 to 187.4 ml (mean 90 ml). The volume of the cauda equina receiving greater than 8 Gy ranged from 0 to 1 ml (mean 0.1 ml). All patients underwent the procedure in an outpatient setting. No acute radiation toxicity or new neurological deficits occurred during the mean follow-up period of 6 months. Pain improved in all 13 patients who were symptomatic prior to treatment. No tumor progression has been documented on follow-up imaging. CONCLUSIONS: Stereotactic radiosurgery was found to be feasible, safe, and effective for the treatment of both benign and malignant sacral lesions. The major potential benefits of radiosurgical ablation of sacral lesions are relatively short treatment time in an outpatient setting and minimal or no side effects. This new technique offers a new and important therapeutic modality for the primary treatment of a variety of sacral tumors or for lesions not amenable to open surgical techniques.",
author = "Gerszten, {Peter C.} and Cihat Ozhasoglu and Burton, {Steven A.} and Welch, {William C.} and Vogel, {William J.} and Atkins, {Barbara A.} and Shalom Kalnicki",
year = "2003",
language = "English (US)",
volume = "15",
journal = "Neurosurgical Focus",
issn = "1092-0684",
publisher = "American Association of Neurological Surgeons",
number = "2",

}

TY - JOUR

T1 - CyberKnife frameless single-fraction stereotactic radiosurgery for tumors of the sacrum.

AU - Gerszten, Peter C.

AU - Ozhasoglu, Cihat

AU - Burton, Steven A.

AU - Welch, William C.

AU - Vogel, William J.

AU - Atkins, Barbara A.

AU - Kalnicki, Shalom

PY - 2003

Y1 - 2003

N2 - OBJECT: The role of stereotactic radiosurgery for the treatment of intracranial lesions is well established. The experience with radiosurgery for the treatment of spinal and sacral lesions is more limited. Sacral lesions should be amenable to radiosurgical treatment similar to that used for their intracranial counterparts. The authors evaluated a single- fraction radiosurgical technique performed using the CyberKnife Real-Time Image-Guided Radiosurgery System for the treatment of the sacral lesion. METHODS: The CyberKnife is a frameless radiosurgery system based on the coupling of an orthogonal pair of x-ray cameras to a dynamically manipulated robot-mounted linear accelerator possessing six degrees of freedom, which guides the therapy beam to the intended target without the need for frame-based fixation. All sacral lesions were located and tracked for radiation delivery relative to fiducial bone markers placed percutaneously. Eighteen patients were treated with single-fraction radiosurgery. Tumor histology included one benign and 17 malignant tumors. Dose plans were calculated based on computerized tomography scans acquired using 1.25-mm slices. Planning treatment volume was defined as the radiographically documented tumor volume with no margin. Tumor dose was maintained at 12 to 20 Gy to the 80% isodose line (mean 15 Gy). Tumor volume ranged from 23.6 to 187.4 ml (mean 90 ml). The volume of the cauda equina receiving greater than 8 Gy ranged from 0 to 1 ml (mean 0.1 ml). All patients underwent the procedure in an outpatient setting. No acute radiation toxicity or new neurological deficits occurred during the mean follow-up period of 6 months. Pain improved in all 13 patients who were symptomatic prior to treatment. No tumor progression has been documented on follow-up imaging. CONCLUSIONS: Stereotactic radiosurgery was found to be feasible, safe, and effective for the treatment of both benign and malignant sacral lesions. The major potential benefits of radiosurgical ablation of sacral lesions are relatively short treatment time in an outpatient setting and minimal or no side effects. This new technique offers a new and important therapeutic modality for the primary treatment of a variety of sacral tumors or for lesions not amenable to open surgical techniques.

AB - OBJECT: The role of stereotactic radiosurgery for the treatment of intracranial lesions is well established. The experience with radiosurgery for the treatment of spinal and sacral lesions is more limited. Sacral lesions should be amenable to radiosurgical treatment similar to that used for their intracranial counterparts. The authors evaluated a single- fraction radiosurgical technique performed using the CyberKnife Real-Time Image-Guided Radiosurgery System for the treatment of the sacral lesion. METHODS: The CyberKnife is a frameless radiosurgery system based on the coupling of an orthogonal pair of x-ray cameras to a dynamically manipulated robot-mounted linear accelerator possessing six degrees of freedom, which guides the therapy beam to the intended target without the need for frame-based fixation. All sacral lesions were located and tracked for radiation delivery relative to fiducial bone markers placed percutaneously. Eighteen patients were treated with single-fraction radiosurgery. Tumor histology included one benign and 17 malignant tumors. Dose plans were calculated based on computerized tomography scans acquired using 1.25-mm slices. Planning treatment volume was defined as the radiographically documented tumor volume with no margin. Tumor dose was maintained at 12 to 20 Gy to the 80% isodose line (mean 15 Gy). Tumor volume ranged from 23.6 to 187.4 ml (mean 90 ml). The volume of the cauda equina receiving greater than 8 Gy ranged from 0 to 1 ml (mean 0.1 ml). All patients underwent the procedure in an outpatient setting. No acute radiation toxicity or new neurological deficits occurred during the mean follow-up period of 6 months. Pain improved in all 13 patients who were symptomatic prior to treatment. No tumor progression has been documented on follow-up imaging. CONCLUSIONS: Stereotactic radiosurgery was found to be feasible, safe, and effective for the treatment of both benign and malignant sacral lesions. The major potential benefits of radiosurgical ablation of sacral lesions are relatively short treatment time in an outpatient setting and minimal or no side effects. This new technique offers a new and important therapeutic modality for the primary treatment of a variety of sacral tumors or for lesions not amenable to open surgical techniques.

UR - http://www.scopus.com/inward/record.url?scp=21644470285&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21644470285&partnerID=8YFLogxK

M3 - Article

VL - 15

JO - Neurosurgical Focus

JF - Neurosurgical Focus

SN - 1092-0684

IS - 2

ER -